ApoCell, Inc.   Report issue

For profit Phase 1
Founded: Houston TX United States (2004)
Status: Acquired by Precision Medicine (2018)

Organization Overview

First Clinical Trial
2016
NCT02935790
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 1 Trials (3)

acy-241 (1 trial)

ipilimumab (yervoy) (1 trial)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Melanoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 3